Welcome to Our New Website!
The Premier Meeting Across all Stakeholders in IO
IO360° offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO to fight a wider range of cancers.
IO360° Delivers 3 Key Benefits
1. Access to KOLs Driving the Science
2. Partnership opportunities with all stakeholders in Immuno-Oncology
3. Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
Keynotes
CEO Keynote
Patrick Hwu, MD
Moffitt Cancer Center
Neoadjuvant Keynote
Laura Esserman, MD, MBA
UCFS
Clinical Evolution of IO
Taha Merghoub, PhD
Weill Cornell Medicine
Analyst Keynote
Andrew Baum, MD
Citi
Data Mining & AI
Ira Mellman, PhD
Genentech
Cancer Vaccines
Margaret Callahan, MD, PhD
MSKCC
VIP Leaders
Neoantigen Cancer Vaccines
Jeffery Weber, MD, PhD
NYU Langone Medical Center
Patient Experience Talk
Kelly Spill Bonito
Patient Advocate
Zeitgeist
Jason Luke, MD, FACP
UPMC Hillman Cancer
Investor Leadership
Rajiv Kaul
Fidelity Investments
AI Visionary Talk
Alexandra Snyder, MD
Generate Bio
Key Topics Covered to date
Biomarkers/Assay Development
Discovery / Preclinical
Imaging Advancements
Playload Modification
Translational Science
AI Enablement for IO
Cancer Vaccines
Cell Therapy
Clinical Developments
Neoadjuvant/Adjuvant Therapy
Business and Investing Aspects
Event Features
.png)
.png)
.png)
.jpg)
Strategic Advisors
2024 Sponsors
